A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
20actual
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-26 | actual | When the study began enrolling |
| Primary completion | 2025-11-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-15 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: Teprotumumab — also filed as Tepezza, AMG 632
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Serum Concentration (Cmax) of Teprotumumab
measured Up to Day 85
Area Under the Serum Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Teprotumumab
measured Up to Day 85
Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUCinf) of Teprotumumab
measured Up to Day 85
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed